C9抗体—艾普蒂

+ +

•  

   

     Western blot analysis of C9 expression in Human fetal liver lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human kidney, using C9 Antibody.    

  
  

The C9 antibody primarily targets the ninth component (C9) of the complement system, a critical part of innate immunity. The complement cascade, including the membrane attack complex (MAC), plays roles in pathogen elimination and immune regulation. C9 is essential for MAC assembly, forming pores in pathogen membranes to induce lysis. Dysregulated MAC activity, however, contributes to tissue damage in autoimmune and inflammatory diseases, such as glomerulonephritis and age-related macular degeneration.

C9 antibodies are research tools used to study MAC formation, inhibition, and its pathological roles. In neurodegenerative disorders like ALS and frontotemporal dementia (FTD), C9orf72 gene mutations produce toxic dipeptide repeats, triggering neuroinflammation via complement activation, including C9-mediated MAC deposition. C9 antibodies help detect MAC in tissues or block its activity in experimental models, aiding therapeutic development.

Recent studies explore C9 antibodies as potential therapeutics to mitigate MAC-driven damage. Challenges include balancing complement inhibition with host defense preservation. Ongoing research focuses on antibody specificity, delivery to target tissues (e.g., the brain), and optimizing pharmacokinetics. These efforts aim to translate C9-targeted strategies into clinical applications for complement-mediated diseases.